Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials

Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo-controlled phase 3 trials enrolled 3,808 adults ages 55-85 with mild cognitive impairment or mild dementia. Over a two-year period, […]

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

NATICK, Mass.–(BUSINESS WIRE)—- $ALUR–Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after […]

Gut health, GLP-1 and AI – the issues shaping ingredients and NPD

At the Next Generation Ingredients 2025 conference, speakers from across the industry explored how health innovation and ethical sourcing are shaping consumer expectations. The post Gut health, GLP-1 and AI – the issues shaping ingredients and NPD appeared first on Just Food.